NetworkNewsBreaks – Predictive Oncology, Inc. (NASDAQ: POAI) Subsidiary Partners with UPMC to Develop AI-Powered Method to Treat Ovarian Cancer
Predictive Oncology’s (NASDAQ: POAI) subsidiary Helomics in July announced a joint collaborative agreement with the University of Pittsburgh School of Medicine (“UPMC”) to study the use of Helomics’ artificial intelligence (“AI”) platform (D-CHIP)(TM) to improve clinical decision making for ovarian cancer patients. The platform will be employed to analyze the genomic and drug response profiles of women with ovarian cancer to establish predictive value in terms of response or non-response to therapy. UPMC Enterprises, the commercialization and innovation arm of UPMC, will fund the work performed under the collaboration. “Helomics has pioneered the testing of drugs on patients’ own tumors…